Edgar Filing: INTERMOLECULAR INC - Form 8-K

INTERMOLECULAR INC Form 8-K April 09, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 5, 2014

Intermolecular, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware 001-35348 20-1616267
(State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.)

3011 N. First Street San Jose, California 95134

(Address of Principal Executive Offices) (Zip Code)

(408) 582-5700

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: INTERMOLECULAR INC - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: INTERMOLECULAR INC - Form 8-K

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

Intellectual Property Licensing Commission Incentive Program for General Counsel and Senior Vice President of Intellectual Property

On April 5, 2014, the Compensation Committee of the Board of Directors of Intermolecular, Inc. (the "Company") approved a new intellectual property licensing commission incentive program for Sandeep Jaggi, J.D., Ph.D., the General Counsel and Senior Vice President of Intellectual Property of the Company. Under the terms of the new program, Dr. Jaggi is eligible to receive one or more future cash payments equal to 0.5% of revenue as and when received by the Company from a specified potential customer engagement, subject to his continued employment.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERMOLECULAR, INC.

Date: April 9, 2014 By: /s/ DAVID E. LAZOVSKY

David E. Lazovsky

President and Chief Executive Officer